Biovac Email Format
Pharmaceutical ManufacturingWestern Cape, South Africa201-500 Employees
Biovac is a South Africa–based pharmaceutical manufacturer established in 2003 to revive vaccine production capacity in Africa. Based in Cape Town, Western Cape, the company seeks to align local biotechnology skills with advanced manufacturing through collaborations with local academic institutions, global pharmaceutical firms, and both the public and private sectors. It produces vaccines on behalf of leading international biopharmaceutical companies and is licensed to manufacture a fully liquid hexavalent vaccine from Sanofi, with plans to begin producing a multivalent pneumococcal vaccine from Pfizer. Biovac supplies more than 15 million vaccine doses annually to South Africa and neighboring countries under strict cold-chain conditions. It maintains in-house product development capabilities and has out-licensed one of its technologies to international manufacturers, while pursuing safeguards against pathogens such as group B streptococcus to address sepsis and meningitis in newborns. Recent developments include the expansion of its Cape Town manufacturing facility to broaden Africa's end-to-end vaccine manufacturing capacity, supported by international partners.